All News Novartis AG

Equities

NOVN

CH0012005267

Market Closed - Swiss Exchange Other stock markets 11:30:12 2024-05-24 am EDT			5-day change	1st Jan Change
91.74 ^CHF	-1.11%		-1.75%	+8.09%

May. 25	Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio	DJ
May. 25	Novartis Presents Results from a Pre-Specified Interim Analysis of the Phase III Align Study	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio	May. 25	DJ
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio	May. 25	GL
Novartis Presents Results from a Pre-Specified Interim Analysis of the Phase III Align Study	May. 25	CI
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo	May. 25	GL
Novartis AG Presents Latest Phase III Fabhalta®? Data in C3 Glomerulopathy	May. 25	CI
NOVARTIS AG : Deutsche Bank remains its Buy rating	May. 24	ZD
Berenberg Raises Price Target on Novartis to CHF77 From CHF74, Maintains Hold Rating	May. 23	MT
NOVARTIS AG : Berenberg remains Neutral	May. 23	ZD
Novartis' Cosentyx Receives Canadian Approval for Hidradenitis Suppurativa Treatment	May. 23	MT
Sandoz: Marketing authorization for Wyost and Jubbonti in the EU	May. 22	CF
Amgen And Sandoz Settle Denosumab BPCIA Litigation	May. 20	AQ
Dpa-AFX Overview: COMPANIES from 16.05.2024 - 15:15	May. 16	DP
Novartis: presents results of tender offer for MorphoSysy	May. 16	CF
Novartis Takeover Bid for MorphoSys Tops Minimum Acceptance Threshold	May. 16	MT
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash	May. 16	GL
Novartis to present results at ASCO and EHA	May. 15	CF
Novartis highlights pioneering innovation in CML with data from Scemblix(R) Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA	May. 15	DJ
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA	May. 15	GL
Novartis receives FDA Breakthrough Therapy designation for Scemblix in 1L CML	May. 13	AQ
Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales	May. 13	DJ